Inhibition Studies of Some Phosphoramides Against Sarcoma 180.

Abstract

Two phosphoramides, N,N[image],N[image]-triethylene phosphoramid (SK3818) and N,N-diethyl-N[image], N[image]-diethylene phosphoramide (SK4614,) have been tested for their ability to retard the development of Sarcoma 180 implanted subcut. into mice. Injns. of the compounds intraperitoneally each day for 1 week starting either 24 hrs. or 4 days after tumor implantation were followed by measurements of tumor diameters for the detn. of degree of inhibition. The approx. ranges of effective doses on a 1 week basis are 2.5-15 mg./K/day for SK3818 and 3-15 mg./K/day for SK 4614. Although for longer term evaluations, the useful dose ranges are smaller, the effective dose ranges are greater than for the best of the compounds previously found in this test procedure to inhibit Sarcoma 180. An effect from SK3818 or 4614 greater than from the other effective compounds has not been observed. The histological evidence of the action of these compounds in normal and tumor tissue reveals a similarity to the action of the N mustards.